BioHiTech Global Inc (NASDAQ:BHTG) has been assigned a consensus broker rating score of 1.50 (Buy) from the two analysts that provide coverage for the company, Zacks Investment Research reports. One equities research analyst has rated the stock with a buy recommendation and one has issued a strong buy recommendation on the company.
Analysts have set a 1 year consensus price target of $3.88 for the company, according to Zacks. Zacks has also given BioHiTech Global an industry rank of 220 out of 255 based on the ratings given to related companies.
Several equities research analysts have recently issued reports on the stock. Maxim Group reissued a “buy” rating and issued a $2.75 price objective on shares of BioHiTech Global in a research report on Thursday. Ascendiant Capital Markets assumed coverage on shares of BioHiTech Global in a research report on Monday, July 22nd. They issued a “buy” rating and a $5.00 price objective for the company.
BioHiTech Global (NASDAQ:BHTG) last posted its quarterly earnings results on Wednesday, August 14th. The company reported ($0.15) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.05) by ($0.10). The company had revenue of $1.05 million for the quarter. BioHiTech Global had a negative return on equity of 267.86% and a negative net margin of 230.53%.
In other BioHiTech Global news, Director James D. Chambers acquired 17,000 shares of the company’s stock in a transaction dated Monday, September 30th. The stock was bought at an average price of $1.79 per share, with a total value of $30,430.00. Insiders bought 24,000 shares of company stock valued at $42,486 in the last three months. Company insiders own 41.90% of the company’s stock.
An institutional investor recently raised its position in BioHiTech Global stock. Vanguard Group Inc. boosted its position in shares of BioHiTech Global Inc (NASDAQ:BHTG) by 38.4% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 85,352 shares of the company’s stock after purchasing an additional 23,701 shares during the period. Vanguard Group Inc. owned approximately 0.57% of BioHiTech Global worth $152,000 at the end of the most recent reporting period. 2.53% of the stock is owned by hedge funds and other institutional investors.
BioHiTech Global Company Profile
BioHiTech Global, Inc provides an environmentally friendly solution for food waste disposal. The Company, through its subsidiaries, BioHiTech America, LLC and BioHiTech Europe Limited, offers its customers various technologies integrating technological, biological and mechanical engineering solutions for the control, reduction and/or reuse of organic waste.
Recommended Story: Why do analysts give a neutral rating?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for BioHiTech Global Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioHiTech Global and related companies with MarketBeat.com's FREE daily email newsletter.